Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.13.5195

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey  

Cokmert, Suna (Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University)
Ellidokuz, Hulya (Department of Preventive Oncology, Insitute of Oncology, School of Medicine, Dokuz Eylul University)
Demir, Lutfiye (Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University)
Fuzun, Mehmet (Department of Surgery, School of Medicine, Dokuz Eylul University)
Astarcioglu, Ibrahim (Department of Surgery, School of Medicine, Dokuz Eylul University)
Aslan, Deniz (Department of Medical Oncology, School of Medicine, Dokuz Eylul University)
Yilmaz, Ugur (Department of Medical Oncology, Medical Park Hospital, Izmir University)
Oztop, Ilhan (Department of Medical Oncology, School of Medicine, Dokuz Eylul University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.13, 2014 , pp. 5195-5200 More about this Journal
Abstract
Background: The purpose of this study was to analyze our series of liver resections for metastatic colorectal carcinoma (mCRC) to determine prognostic factors affecting survival and to evaluate the potential roles of neoadjuvant or adjuvant chemotherapy. Materials and Methods: Ninety-nine patients who underwent metastasectomy for liver metastases due to colorectal cancer at the Department of Medical Oncology, 9 Eylul University Hospital between 1996 and 2010 were evaluated in this study. The patients were followed through July 2013. Demographic, perioperative, laboratory, radiological and chemotherapy as well as survival data were obtained by retrospective chart review. Results: In 47 (47.5%) patients, liver metastases were unresectable at initial evaluation; the remaining 52 (52.5%) patients exhibited resectable liver metastases. Simultaneous hepatic resection was applied to 52 (35.4%) patients with synchronous metastasis, whereas 5 (64.5%) patients underwent hepatic resection after neoadjuvant chemotherapy. Forty-two patients with metachronous metastasis underwent hepatic resection following neoadjuvant chemotherapy. R0 resection was obtained in 79 (79.8%) patients. A second hepatectomy was performed in 22 (23.2%) patients. Adjuvant chemotherapy was given to 85 (85.9%) patients after metastasectomy. The median disease-free and overall survivals after initial metastasectomy were 12 and 37 months, respectively, the 1-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) rates being 46.5%, 24.3% and 17.9%and 92.3%, 59.0% and 39.0%, respectively. On multivariate analysis, the primary tumor site, tumor differentiation, resection margin and DFS were independent factors predicting better overall survival. Conclusions: In selected cases, hepatic metastasectomy for mCRC to the liver can result in long-term survival. Neoadjuvant chemotherapy did not exert a positive effect on DFS or OS. Adjuvant chemotherapy also did not appear to impact DFS and OS.
Keywords
Liver metastases; colorectal cancer; metastasectomy; survival; prognostic factors;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994). Factors influencing the natural history of colorectal liver metastases. Lancet, 343, 1405-10.   DOI   ScienceOn
2 Rebecca Siegel, Carol De Santis, Katherine Virgo, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41.   DOI
3 Reddy RH, Kumar B, Shah R, et al (2004). Staged pulmonary and hepatic metastasectomy in colorectal cancer is it worth it? Eur J Cardiothorac Surg, 25, 151-4.   DOI   ScienceOn
4 Sato T, Konishi K, Yabushita K, et al (1998). The time interval between primary colorectal carcinoma resection to occurrence of liver metastases is the most important factor for hepatic resection. Analysis of total course following primary resection of colorectal cancer. Int Surg, 83, 340-42.
5 Sobin LH, Gospodarowicz MK (2009). Wittekind Ch Eds. TNM classification of malignant tumors, 7th ed. wiley-blackwell, oxford. 310 pages.
6 Mitry E, Fields ALA, Bleiberg H, et al (2008). Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol, 26, 4906-11.   DOI   ScienceOn
7 Kato T, Yasui K, Hirai T, et al (2003). Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum, 46, 22-31.
8 Lopez-Gomez M, Cejas P, Merino M, et al (2012) Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? Clin Transl Oncol, 14, 641-58.   DOI   ScienceOn
9 Morise Z, Sugioka A, Fujita J, et al (2006). Does repeated surgery improve the prognosis of colorectal liver metastases? J Gastrointest Surg, 10, 6-11.   DOI   ScienceOn
10 Nikfarjam M, Shereef S, Kimchi ET, et al (2009). Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol, 16, 1860-7.   DOI
11 Nordlinger B, Sorbye H, Debois M, et al (2005). Feasibility and risks of preoperative chemotherapy with FOLFOX 4 and surgery for resectable colorectal liver metastases: Interim results of the EORTC Intergroup randomized phase III study 40983. J Clin Oncol, 23, 253.
12 Pawlik TM, Choti MA (2007). Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg, 11, 1057-77.   DOI   ScienceOn
13 Gallinger S, Biagi JJ, Fletcher GG, et al (2013). Liver resection for colorectal cancer metastases. Curr Oncol, 20, 255-65.   DOI   ScienceOn
14 Dong H, Tang J, Li LH, et al (2013). Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases. Asian Pac J Cancer Prev, 14, 909-13.   과학기술학회마을   DOI   ScienceOn
15 Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.   DOI   ScienceOn
16 Ike H, Shimada H, Togo S, et al (2002). Sequential resection of lung metastases following partial hepatectomy for colorectal cancer. Br J Surg, 89, 1164-8.   DOI   ScienceOn
17 Fong Y, Fortner J, Sun RL, et al (1999). Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg, 230, 309-18.   DOI   ScienceOn
18 Giacchetti S, Itzhaki M, Gruia G, et al (1999). Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol, 10, 663-9.   DOI   ScienceOn
19 Hsu Y-N, Lin J-K, Chen W-S, et al (2011). A new classification scheme for recurrent or metastatic colon cancer after liver metastasectomy. J Chinese Med Assoc, 74, 493-9.   DOI   ScienceOn
20 Jain S, Sacchi M, Vrachnos P, et al (2005). Recent advances in the treatment of colorectal liver metastases. Hepatogastroenterology, 52, 1567-84.
21 Jones RP, Jackson R, Dunne DFJ, et al (2012). Systematic review and metaanalysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg, 99, 477-86.   DOI   ScienceOn
22 Jones RP, Malik HZ, Fenwick SW, et al (2013) Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Oncol, 39, 807-11.   DOI   ScienceOn
23 Chua TC, Liauw W, Koong HN, et al (2011). Surgical therapies in metastatic colorectal cancer with a potential for cure. Am J Clin Oncol, 34, 326-31.   DOI   ScienceOn
24 Couinaud C (1954). Anatomic principles of left and right regulated hepatectomy: technics. J Chir (Paris), 70, 933-66.
25 Castaing D, Vibert E, Ricca L, et al (2009). Oncologic results of laparoscopic versus open hepatectomy in two specialized centers. Ann Surg, 250, 849-55.   DOI   ScienceOn
26 Cui YL, Li HK, Zhou HY, et al (2013). Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. Asian Pac J Cancer Prev, 14, 1003-7.   과학기술학회마을   DOI   ScienceOn
27 Van Cutsem E, Nordlinger B, Adam R, et al (2006). Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 42, 2212-21.   DOI   ScienceOn
28 Portier G, Elias D, Bouche O, et al (2006). Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol, 24, 4976-82.   DOI   ScienceOn